Divi's Laboratories (DIVISLAB) Stock Overview
Engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
DIVISLAB Community Fair Values
Create NarrativeSee what 17 others think this stock is worth. Follow their fair value or set your own to get alerts.
Divi's Laboratories Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹6,655.00 |
| 52 Week High | ₹7,071.50 |
| 52 Week Low | ₹4,955.00 |
| Beta | 0.18 |
| 1 Month Change | 16.97% |
| 3 Month Change | 4.61% |
| 1 Year Change | 12.99% |
| 3 Year Change | 75.99% |
| 5 Year Change | 107.39% |
| Change since IPO | 75,417.73% |
Recent News & Updates
Divi's Laboratories Limited's (NSE:DIVISLAB) Share Price Could Signal Some Risk
Sep 06
Divi's Laboratories Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Aug 10Most Shareholders Will Probably Agree With Divi's Laboratories Limited's (NSE:DIVISLAB) CEO Compensation
Aug 05Recent updates
Divi's Laboratories Limited's (NSE:DIVISLAB) Share Price Could Signal Some Risk
Sep 06Divi's Laboratories Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Aug 10Most Shareholders Will Probably Agree With Divi's Laboratories Limited's (NSE:DIVISLAB) CEO Compensation
Aug 05Here's What Analysts Are Forecasting For Divi's Laboratories Limited (NSE:DIVISLAB) After Its Yearly Results
Jul 17Divi's Laboratories Limited (NSE:DIVISLAB) Investors Are Less Pessimistic Than Expected
Apr 10Divi's Laboratories Limited's (NSE:DIVISLAB) Shareholders Might Be Looking For Exit
Dec 25
Tactical Expansions And Innovation Could Offset Generic Pricing Pressures And Boost Profitability
Strategic investments in peptide synthesis and greenfield expansion enhance future revenue potential through capacity and product line growth.Shareholder Returns
| DIVISLAB | IN Life Sciences | IN Market | |
|---|---|---|---|
| 7D | 1.4% | -0.5% | 0.7% |
| 1Y | 13.0% | 1.8% | 2.3% |
Return vs Industry: DIVISLAB exceeded the Indian Life Sciences industry which returned 1.8% over the past year.
Return vs Market: DIVISLAB exceeded the Indian Market which returned 2.3% over the past year.
Price Volatility
| DIVISLAB volatility | |
|---|---|
| DIVISLAB Average Weekly Movement | 3.8% |
| Life Sciences Industry Average Movement | 5.1% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in IN Market | 8.4% |
| 10% least volatile stocks in IN Market | 3.2% |
Stable Share Price: DIVISLAB has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: DIVISLAB's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 10,542 | Kiran Divi | www.divislabs.com |
Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as beta carotene, astaxanthin, lycopene, and canthaxanthin, as well as lutein and vitamins used in the food, beverage, dietary supplement, pet food, and feed industries. It also exports its products.
Divi's Laboratories Limited Fundamentals Summary
| DIVISLAB fundamental statistics | |
|---|---|
| Market cap | ₹1.77t |
| Earnings (TTM) | ₹23.06b |
| Revenue (TTM) | ₹96.52b |
Is DIVISLAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DIVISLAB income statement (TTM) | |
|---|---|
| Revenue | ₹96.52b |
| Cost of Revenue | ₹38.28b |
| Gross Profit | ₹58.24b |
| Other Expenses | ₹35.18b |
| Earnings | ₹23.06b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Nov 07, 2025
| Earnings per share (EPS) | 86.87 |
| Gross Margin | 60.34% |
| Net Profit Margin | 23.89% |
| Debt/Equity Ratio | 0.03% |
How did DIVISLAB perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/30 23:04 |
| End of Day Share Price | 2025/10/30 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Divi's Laboratories Limited is covered by 50 analysts. 29 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Prashant Nair | Ambit Capital |
| Nitin Bhasin | Ambit Capital |
| Ashwin Mehta | Ambit Capital |